Minimal Residual Disease (MRD) Testing

Natera alleges Inivata infringes its US Patent Nos. 10,262,755 and 10,597,709, which cover cancer monitoring and molecular residual disease testing.

Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.

The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.

In a note to investors, Piper Sandler analysts wrote that the upgrade reflects increased confidence in Grail and Illumina's core next-generation sequencing business.

In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.

Development revenues for the Seattle-based firm ticked up 5 percent to $15.0 million in Q3, partially offset by a 3 percent dip in sequencing revenues.

Product revenues increased 39 percent year over year to $93.3 million, while license and other revenues were down 56 percent to $4.9 million.